| Margins | Targeting 62% IVD, 45% MedTech, and 12% Solar EPC gross margins. |
|---|---|
| Order book | ₹3,000+ Cr renewable energy pipeline; ~₹2,000 Cr currently secured. |
| Demand visibility | Strong; backed by National Solar Mission and National Sickle Cell Mission. |
| Management confidence | High; citing 27-year legacy and strategic pivots into high-margin segments. |
Growth
No Q1 FY27 specific financials provided; highlights include securing a maiden $1M US export order and 20.8% CAGR MedTech market tailwinds.
Outlook
Vision 2030 targets $3B valuation, 2,000+ pathology labs, and 1,000 renal units by March 2028. FY27 FPO and FY28 demerger planned.
Risks
Dependence on government contracts (UPNEDA, BREDA) and high import substitution requirements in the Indian medical device sector.
Investor Presentation filed with BSE, NSE: KRATOSENER. Summary written with AI assistance from the document.
Lords Mark Industries Ltd: key numbers
- Share price
- ₹92.77
- Market cap
- ₹3,958 Cr
- Revenue (annual)
- ₹684.8 Cr
- Net profit (annual)
- ₹48.59 Cr
- P/E (TTM)
- 47.4×Sector 22.0×
- Promoter holding
- 79.84%-1.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lords Mark Industries Ltd
All →Lords Mark Industries Business Update
Promoter Sachidanand Hariram Upadhyay proposed reinvesting proceeds from his prior sale of shares into the company's medical device unit expansion.
- Value
- ₹87.38 Cr
Lords Mark Industries Business Update
Lord’s Mark Industries has advanced its AI-powered breast cancer screening technology to final clinical trial stages. The company targets a global commercial launch by April 2027.
Lords Mark Industries Promoter Selling: ₹87.39 Cr
Promoter Director Mr. Sachidanand H Upadhyay sold 1.04 crore shares on BSE for ₹87.39 Crore. Stake reduced from 77.54% to 75.11%.
- Value
- ₹87.39 Cr
Lords Mark Industries Promoter Selling
Lord's Mark promoter Sachidanand Upadhyay disposed 1.04 crore shares via open market, cutting his stake from 77.54% to 75.11%.
Lords Mark Industries Capacity Expansion
Lord's Mark Industries completed Phase I Silvassa expansion, adding 18 surgical/orthopaedic SKUs (36 to 54). Commercial operations commence October 11, 2026.
- surgical and orthopaedic product SKUs
- 54 SKUs
Lords Mark Industries IPO
The board approved a proposal for an Offer for Sale (OFS) of up to 3% of equity capital by promoters to meet minimum public shareholding requirements.